Literature DB >> 31232701

Low risk to retina from sustained suppression of VEGF.

Peter A Campochiaro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31232701      PMCID： PMC6668674          DOI： 10.1172/JCI129861

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  17 in total

1.  Neurovascular crosstalk between interneurons and capillaries is required for vision.

Authors:  Yoshihiko Usui; Peter D Westenskow; Toshihide Kurihara; Edith Aguilar; Susumu Sakimoto; Liliana P Paris; Carli Wittgrove; Daniel Feitelberg; Mollie S H Friedlander; Stacey K Moreno; Michael I Dorrell; Martin Friedlander
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

2.  Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration.

Authors:  Timothy K Maclachlan; Michael Lukason; Margaret Collins; Robert Munger; Elisabete Isenberger; Cindy Rogers; Shana Malatos; Elizabeth Dufresne; James Morris; Roberto Calcedo; Gabor Veres; Abraham Scaria; Laura Andrews; Samuel Wadsworth
Journal:  Mol Ther       Date:  2010-11-30       Impact factor: 11.454

3.  Targeted deletion of Vegfa in adult mice induces vision loss.

Authors:  Toshihide Kurihara; Peter D Westenskow; Stephen Bravo; Edith Aguilar; Martin Friedlander
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

4.  VEGF/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models.

Authors:  Da Long; Yogita Kanan; Jikui Shen; Sean F Hackett; Yuanyuan Liu; Zibran Hafiz; Mahmood Khan; Lili Lu; Peter A Campochiaro
Journal:  JCI Insight       Date:  2018-05-17

5.  Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes.

Authors:  Roomasa Channa; Raafay Sophie; Saghar Bagheri; Syed M Shah; Jiangxia Wang; Olukemi Adeyemo; Akrit Sodhi; Adam Wenick; Howard S Ying; Peter A Campochiaro
Journal:  Am J Ophthalmol       Date:  2014-09-08       Impact factor: 5.258

6.  Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.

Authors:  Juan E Grunwald; Ebenezer Daniel; Jiayan Huang; Gui-Shuang Ying; Maureen G Maguire; Cynthia A Toth; Glenn J Jaffe; Stuart L Fine; Barbara Blodi; Michael L Klein; Alison A Martin; Stephanie A Hagstrom; Daniel F Martin
Journal:  Ophthalmology       Date:  2013-09-29       Impact factor: 12.079

Review 7.  Vascular endothelial growth factor: basic science and clinical progress.

Authors:  Napoleone Ferrara
Journal:  Endocr Rev       Date:  2004-08       Impact factor: 19.871

8.  Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors.

Authors:  Magali Saint-Geniez; Arindel S R Maharaj; Tony E Walshe; Budd A Tucker; Eiichi Sekiyama; Tomoki Kurihara; Diane C Darland; Michael J Young; Patricia A D'Amore
Journal:  PLoS One       Date:  2008-11-03       Impact factor: 3.240

9.  Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.

Authors:  Frank G Holz; Ramin Tadayoni; Stephen Beatty; Alan Berger; Matteo G Cereda; Rafael Cortez; Carel B Hoyng; Philip Hykin; Giovanni Staurenghi; Stephanie Heldner; Timon Bogumil; Theresa Heah; Sobha Sivaprasad
Journal:  Br J Ophthalmol       Date:  2014-09-05       Impact factor: 4.638
View more
  5 in total

1.  Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice.

Authors:  Sikai Ling; Shiqi Yang; Xinde Hu; Di Yin; Yao Dai; Xiaoqing Qian; Dawei Wang; Xiaoyong Pan; Jiaxu Hong; Xiaodong Sun; Hui Yang; Soren Riis Paludan; Yujia Cai
Journal:  Nat Biomed Eng       Date:  2021-01-04       Impact factor: 25.671

2.  Targeting circular RNA-MET for anti-angiogenesis treatment via inhibiting endothelial tip cell specialization.

Authors:  Mu-Di Yao; Qin Jiang; Yan Ma; Yan Zhu; Qiu-Yang Zhang; Ze-Hui Shi; Chen Zhao; Biao Yan
Journal:  Mol Ther       Date:  2022-01-07       Impact factor: 11.454

3.  Retinal and Choroidal Vascular Diseases: Past, Present, and Future: The 2021 Proctor Lecture.

Authors:  Peter A Campochiaro
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-11-01       Impact factor: 4.799

Review 4.  Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma.

Authors:  Shenglong Li
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

5.  Low-Dose Recombinant Adeno-Associated Virus-Mediated Inhibition of Vascular Endothelial Growth Factor Can Treat Neovascular Pathologies Without Inducing Retinal Vasculitis.

Authors:  Shun-Yun Cheng; Yongwen Luo; Anneliese Malachi; Jihye Ko; Qin Su; Jun Xie; Bo Tian; Haijiang Lin; Xiao Ke; Qiang Zheng; Phillip W L Tai; Guangping Gao; Claudio Punzo
Journal:  Hum Gene Ther       Date:  2021-07       Impact factor: 5.695
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.